Table 1.
Country of treatment by World Health Organization Region of children and adolescents with rifampicin-resistant tuberculosis in the analysis cohort (n=20,395)
| Country | N (%) |
|---|---|
| African Region (AFR) | |
| South Africa | 5,954 (29.2%) |
| Country not specified* | 23 (0.1%) |
| AFR Total | 5,977 |
| Region of the Americas (AMR) | AMR Total: |
| Brazil | 125 (0.6%) |
| Peru | 234 (1.1%) |
| United States | 9 (<0.1%) |
| Country not specified* | 31 (0.2%) |
| AMR Total | 399 |
| South-East Asia Region (SEAR) | |
| India | 12,898 (63.2 %) |
| Country not specified* | 29 (0.1%) |
| SEAR Total | 12927 |
| European Region (EUR) | |
| Austria | 8 (<0.1%) |
| Belarus | 5 (<0.1%) |
| Georgia | 42 (0.2%) |
| Germany | 10 (<0.1%) |
| Latvia | 52 (0.3%) |
| Netherlands | 3 (<0.1%) |
| Russia | 53 (0.3%) |
| Spain | 25 (0.1%) |
| Tajikistan | 250 (1.2%) |
| Ukraine | 6 (<0.1%) |
| Uzbekistan | 327 (1.6%) |
| Country not specified* | 43 (0.2%) |
| EUR Total | 824 |
| Eastern Mediterranean Region (EMR) | |
| Pakistan | 210 (1.0%) |
| Country not specified* | 50 (0.2%) |
| EMR Total | 260 |
| Western Pacific Region (WPR) | |
| South Korea | 3 (<0.1%) |
| Taiwan | 4 (<0.1%) |
| Country not specified* | 1 (<0.1%) |
| WPR Total | 8 |
*
Country not specified indicates that the dataset did not report country of treatment in order to maintain anonymity but did report WHO region of treatment.